Strategic Thrusts Banner
Engineering CELLS,
   Engineering RESPONSES
28
Jun 2017

Study Pinpoints Best Stage of Stem Cell Differentiation for Use in Treating Parkinson’s Disease

Studies indicate that replacing damaged brain cells with those derived from human embryonic stem cells might lead to an effective treatment for Parkinson’s disease. But what has not been determined is the optimal stage during differentiation of the stem cells that the transplantation should take place to gain the best results.

27
Feb 2017

Waters Honors Singapore’s Bioprocessing Technology Institute (BTI) for Glycoscience Research

At a ceremony and symposium today, Waters Corporation welcomed into its Centers of Innovation Program the Bioprocessing Technology Institute (BTI), a research institute under Singapore’s Agency for Science, Technology and Research (A*STAR). BTI is the first research institute1 focused on glycobiology to participate in the Waters Centers of Innovation Program. Glycans, or sugars, are one of the four fundamental classes of macromolecules that comprise living systems. BTI’s glycan research is aimed at finding novel cancer markers and elucidating glycosylation pathways that could pave the way for new therapeutic strategies.

21
Jun 2016

Waters Collaborates with Singapore’s Bioprocessing Technology Institute to Develop New Strategies to Identify Cancer Markers and Probe Cancer Biology

Waters Corporation today announced a joint effort with the Bioprocessing Technology Institute (BTI), a research institute within Singapore's Agency for Science, Technology and Research (A*STAR), to develop new methods of finding cancer markers and elucidating glycosylation pathways that could pave the way for new therapeutic strategies. As part of the research collaboration, Waters and BTI will develop a GSL head group database containing Glucose Unit (GU) retention times1 and collision cross section (CCS) values in an effort to compile an experimental library for disease-related glycosphingolipid (GSL) glycans together with a glycan/ MS spectral library.

02
Apr 2016

Nestlé expands research and innovation activities in Asia with new Research Centre in Singapore’s Biopolis

Nestlé announced today that it will expand research and innovation activities in Asia with the establishment of Nestlé Research Centre (NRC) Asia in Biopolis, the biomedical research hub of Singapore. The expansion builds on Nestlé’s strategic innovation partnership with Singapore’s Agency for Science, Technology and Research (A*STAR), and provides a new base for Nestlé Research Centre, with a focus on Healthy Ageing.

26
Jan 2016

SCIEX and A*STAR’s Bioprocessing Technology Institute Enter Multi-Year Collaboration to Advance Biologics Research & Development in Singapore

SCIEX, a global leader in life science analytical technologies, and the Bioprocessing Technology Institute (BTI), a research institute under Singapore’s Agency for Science, Technology and Research (A*STAR) with expertise in bioprocess science and engineering, today announced a collaboration to advance research and development in the area of biologics in Singapore.

14
Jul 2015

Agilent Technologies and A*STAR’s Bioprocessing Technology Institute Collaborate on New Bioanalytical Methodologies

Agilent Technologies Inc. and the Bioprocessing Technology Institute (BTI), a research institute of Singapore’s Agency for Science, Technology and Research (A*STAR) today announced that they will collaborate on new analytical approaches to analyzing specific protein-linked sugar compounds.

26
Sep 2014

Protecting the body from itself

Scientists from A*STAR’s Bioprocessing Technology Institute (BTI) have established a clearer relationship between two cells which serve our body’s natural defence mechanisms against diseases and infections. Their findings, published in the prestigious journal CELL REPORTS, will help the medical community better understand autoimmunity and could pave the way for treatment of autoimmune diseases.

01
Sep 2014

Understanding and improving the body's fight against pathogens

Scientists from A*STAR’s Bioprocessing Technology Institute (BTI) have uncovered the crucial role of two signalling molecules, DOK3 and SHP1, in the development and production of plasma cells. These discoveries, published in two prestigious journals PNAS and Nature Communications, advance the understanding of plasma cells and the antibody response, and may lead to optimisation of vaccine development and improved treatment for patients with autoimmune diseases such as lupus and tumours such as multiple myeloma.

14
Jul 2014

A*STAR partners Roche to develop new cancer therapeutics

A*STAR’s Bioprocessing Technology Institute (BTI) has entered into an agreement with one of the world’s largest pharmaceutical company, Roche, to identify novel drug candidates for the detection and treatment of cancer. The partnership brings together BTI’s capabilities in novel antibody discovery and Roche’s expertise in developing monoclonal antibody (mAbs) therapeutics, opening up the possibility of improved treatment for cancer, a leading cause of death worldwide.

12
Feb 2014

A*STAR's Bioprocessing Technology Institute (BTI) partners South Korean Institutes to advance glycomics research in Asia

A*STAR’s Bioprocessing Technology Institute (BTI) today signed Memorandums of Understanding (MoUs) with Korea Basic Science Institute (KBSI) and Chungnam National University’s Graduate School of Analytics Science and Technology (GRAST) to advance collaboration between Singapore and South Korea in the field of glycomics in Asia. The agreements were signed by the three organisations at the first Singapore-South Korea Symposium on Glycomics (SKSG), held from 12 – 13 February 2014.

23
May 2013

Agilent Technologies, University of Rouen and A*STAR’S Bioprocessing Technology Institute to Further Innovation in Biopharmaceuticals and Glycomics

Agilent Technologies Inc. (NYSE: A), the Glyco-MEV laboratory at the University of Rouen, in France, and the Bioprocessing Technology Institute at the Agency for Science, Technology and Research (A*STAR) in Singapore, have signed a memorandum of understanding to work together to develop tools to effectively analyze biologics and vaccines.

19
Mar 2013

A*STAR’S Antibody Technology Bags Regional Award

VeriStem Technologies, a spin-off from A*STAR’s Bioprocessing Technology Institute (BTI), has been awarded the Biospectrum Asia-Pacific Emerging Companies of the Year Award 2013. Shortlisted from start-up companies spanning the biotechnology, medical technology, and pharmaceutical sectors across the Asia-Pacific region, winners are chosen for developing innovative technology that has the potential to bring out revolutionary changes in the healthcare industry. As one of this year’s recipients, VeriStem Technologies has won the award for its highly-effective tools that enable the development and manufacture of safe stem cell therapies.

13
Dec 2012

Singapore Scientists Identify New Biomarker for Cancer in Bone Marrow

Singapore scientists have identified FAIM, a molecule that typically prevents cell death, as a potential biomarker to identify an incurable form of cancer in the bone marrow. Patients with this form of cancer usually do not get cured with current standard treatments such as chemotherapy and stem cell transplantation, with an average survival of only about four years. FAIM could thus be a therapeutic target in these patients, as drugs developed to target the molecule could destroy multiple myeloma cells and hence eradicate the cancer.

11
May 2012

A*STAR Scientists Discover ‘Switch’ To Boost Anti-Viral Response To Fight Infectious Diseases

Singapore scientists from Bioprocessing Technology Institute (BTI) under the Agency of Science, Technology and Research (A*STAR) have for the first time, identified the molecular ‘switch’ that directly triggers the body’s first line of defence against pathogens, more accurately known as the body’s “innate immunity”. The scientists found that this ‘switch’ called Bruton’s tyrosine kinase (BTK) when turned on, activates the production of interferons - a potent class of virus killers that enables the body to fight harmful pathogens such as dengue and influenza viruses.

28
Nov 2011

Singapore scientists lead human embryonic stem cell study to advance the field of regenerative medicine research

Researchers from A*STAR Singapore took lead roles in a study that identified a portion of the genome mutated during long-term culture of human embryonic stem cells (hESCs). The study was a worldwide collaboration, led by Drs Peter Andrews of the University of Sheffield (UK), Paul Robson of the Genome Institute of Singapore (GIS), Steve Oh of Singapore’s Bioprocessing Technology Institute (BTI), and Barbara Knowles and others in the international stem cell community. The GIS, IMB and BTI are research institutes under the umbrella of the Agency for Science, Technology and Research, (A*STAR), Singapore.

16
Nov 2010

Congratulations to Professor Lam Kong Peng on receiving the Prestigious Arthur Kornberg Memorial Award

Professor Lam Kong Peng, Scientific Director of A*STAR’s Bioprocessing Technology Institute (BTI), has been honoured with the Arthur Kornberg Memorial Award by the Asia Pacific International Molecular Biology Network (A-IMBN), one of Asia's key organisations for research in molecular biology and biotechnology based in Seoul, Korea. The award, started in 2008, is given to a promising scientist who has demonstrated excellence in research relevant to the needs of humanity.

30
Nov 2009

Society for Biological Engineering Honors Prof Wei-Shou Hu and Prof Miranda Yap

NEW YORK CITY – The Society for Biological Engineeri ng (SBE), a technological community within the American Institute of Chemical Engineer s (AIChE), has awarded its first service awards to Drs. Wei-Shou Hu, a professor at th e University of Minnesota, and Mi randa Yap, executive director of the Bioprocessing Technology Inst itute in Singapore.

26
Nov 2009

Congratulations to Prof Miranda Yap on receiving the APBioChEC 2009 Award and the SBE Distinguished Service Award

A*STAR congratulates Prof Miranda Yap, Executive Director of the Bioprocessing Technology Institute (BTI), on receiving two awards for her outstanding contributions to the field of biological and biochemical engineering.

20
Nov 2009

A*STAR collaborates with CIMIT to enhance the environment for growing the medical technology industry as part of the drive to transform Singapore into a knowledge-based innovation-driven economy

A*STAR collaborates with CIMIT to enhance the environment for growing the medical technology industry as part of the drive to transform Singapore into a knowledge-based innovation-driven economy. Local doctors, BMS scientists and engineers given the boost to create engineering solutions to medical problems.

28
Sep 2009

Professor Miranda Yap honoured for developing Singapore’s biologics industry and nurturing young talent for R&D sector

Eight outstanding research scientists and engineers will receive the inaugural President’s Science and Technology Awards (PSTA) from President S R Nathan at the award ceremony held at the Istana on 28 September 2009. The PSTAs are the highest honours bestowed on exceptional individuals and teams for their excellent achievements in science and technology, and their outstanding contributions to the research and development landscape in Singapore.

10
Jan 2009

Singapore’s Bioprocessing Technology Institute partners Glaxo SmithKline Biologicals SA in Vaccine R&D

A*STAR’s Bioprocessing Technology Insitute (BTI) and GSK Biologicals SA Belgium have sealed an agreement to co llaborate in three vaccine and adjuvant system related research projects. This collaboration, which will integrate BTI’s expertise in bioprocessing with GSK’s capabilit ies in biologics, aims to bring about new approaches to vaccine development and production.

09
Sep 2008

Beating to the Rhythm of Heart Research in Singapore

Scientists from the Institute of Medical Biology (IMB) and Bioprocessing Technology Institute (BTI), under Singapore’s Agency for Science, Technology and Research (A*STAR), and the University Medical Center Utrecht in the Netherlands have jointly developed a novel way to improve survival and recovery rate after a heart attack[1]. This method, the first non-cell based therapeutic application of human embryonic stem cells (hESCs), entails using secretions from stem cells.

07
Apr 2008

BTI Develops First Cytotoxic Antibody against Undifferentiated Stem Cells

A*STAR’s Bioprocessing Technology Institute (BTI) researchers have developed a monoclonal antibody that is able to specifically target undifferentiated human embryonic stem cells (hESCs) and cause them to undergo induced cell death. The research team’s findings were published online on 20 th March 2008 in the journal Stem Cells .

07
Apr 2008

Bioprocessing Technology Institute Forms Consortium for Chinese Hamster Ovary (CHO) Cells Genomic Research

Singapore, 3 March 2006 - A * STAR Bioprocessing Technology Institute ( BTI ) and the University of Minnesota , USA has jointly organized the formation of a consortium to further the development of genomic research tools for Chinese Hamster Ovary ( CHO ) cell lines .

28
Feb 2006

Head of Singapore Research Institute Elected to Prestigious U.S. National Academy of Engineering

Singapore,28 February 2006 Professor Miranda Yap, Executive Director of A*STAR Bioprocessing Technology Institute (BTI) was recently named a Foreign Associate of the U.S.National Academy of Engineering for the year 2006. She was elected for her outstanding achievements in education,research,and management in the field of mammalian cell culture. In depth understanding and engineering skills are required to grow mammalian cells in culture in large quantities. Also elected were 8 other Foreign Associates and 76 new members.The announcement was made on 10 February by the academy.

30
Jun 2005

Young BTI Scientists Win International Recognition for Outstanding Research Posters

Two researchers from the Bioprocessin g Technology Institute (BTI) have won poster awards at two separate internatio nal scientific conferences. The two PhD students, Danny Wong, 29, and Dave Ow, 32, participated in the 19 th European Society of Animal Cell Technology (ESACT) Conference in the UK and the Asia- Pacific Biochemical Engineering Conference (APBioChEC’05) in Korea respectively.

21
Apr 2004

A*STAR's Bioprocessing Technology Institute Joins The Biopolis Community

A*STAR’s Bioprocessing Technology Instit ute (BTI) has a new home and vision. Marking its move to the Biopolis, the resea rch institute hosted more than 400 guests at its inaugural Open House at Biopolis today, which was held in conjunction with the Singapore Biologics Manufacturing Conference (SBMC).

29
Jan 2003

Singapore Opens First cGMP Biopharmaceutical Manufacturing Facility in the Region

Opening address by George Yeo, Minister for Trade & Industry, at the opening of the Biopharmaceutical Manufacturing Technology Centre (BMTC) cGMP facility on 29 January 2003 at 4.00 pm.